welcome aboard guys, plan to follow this closely in the aftermarket and wouldn't be surprised to see this thread become fairly popular in due course.
Red I assume you will keep your market intelligence open to us!
I think that the main thing that will drive GBI in the short term is further demonstration of path lab players getting behind PapType (remember the Sonic deal is non-exclusive) and then development of new tests on the AmpaSand platform along with multiplexing.
The big blue sky will kick in with QSand developments.
Qsand as an ultra-sensitive biosensor can completely remove the need for PCR. PCR has so far earned approximately US$2 billion in royalties for the various rights-holders over the years and Roche charges approx an 18% royalty for its RT-PCR
also less headline grabbing but just as important will be ISO 13485 accreditation and GMP, then Sonic internal validation of PapType.
cheers
- Forums
- ASX - By Stock
- GBI
- do yourself and me a favour in this great ipo
do yourself and me a favour in this great ipo, page-12
-
- There are more pages in this discussion • 15 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add GBI (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
I88
INFINI RESOURCES LIMITED
Charles Armstrong, CEO
Charles Armstrong
CEO
SPONSORED BY The Market Online